4880 Stock Overview
Engages in the regenerative medicine-related businesses in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CellSource Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥614.00 |
| 52 Week High | JP¥1,610.00 |
| 52 Week Low | JP¥556.00 |
| Beta | 0.18 |
| 1 Month Change | -23.06% |
| 3 Month Change | -20.67% |
| 1 Year Change | -60.41% |
| 3 Year Change | -82.94% |
| 5 Year Change | -44.24% |
| Change since IPO | -21.28% |
Recent News & Updates
Recent updates
Risks Still Elevated At These Prices As CellSource Co., Ltd. (TSE:4880) Shares Dive 31%
Apr 08
We Think That There Are More Issues For CellSource (TSE:4880) Than Just Sluggish Earnings
Dec 20Some CellSource Co., Ltd. (TSE:4880) Shareholders Look For Exit As Shares Take 25% Pounding
Dec 19A Look At The Fair Value Of CellSource Co., Ltd. (TSE:4880)
Aug 13Shaky Earnings May Not Tell The Whole Story For CellSource (TSE:4880)
Jun 20Shareholder Returns
| 4880 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -0.3% | 1.6% | 6.3% |
| 1Y | -60.4% | -26.2% | -5.8% |
Return vs Industry: 4880 underperformed the JP Life Sciences industry which returned -26.2% over the past year.
Return vs Market: 4880 underperformed the JP Market which returned -5.8% over the past year.
Price Volatility
| 4880 volatility | |
|---|---|
| 4880 Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in JP Market | 9.3% |
| 10% least volatile stocks in JP Market | 3.0% |
Stable Share Price: 4880 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4880's weekly volatility (7%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 157 | Takashi Sawada | www.cellsource.co.jp |
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy, as well as manufacturing processed cells. It is also involved in the development and sale of Signalift series of anti-aging products, including a serum.
CellSource Co., Ltd. Fundamentals Summary
| 4880 fundamental statistics | |
|---|---|
| Market cap | JP¥12.16b |
| Earnings (TTM) | JP¥48.54m |
| Revenue (TTM) | JP¥4.03b |
250.6x
P/E Ratio3.0x
P/S RatioIs 4880 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4880 income statement (TTM) | |
|---|---|
| Revenue | JP¥4.03b |
| Cost of Revenue | JP¥1.91b |
| Gross Profit | JP¥2.12b |
| Other Expenses | JP¥2.07b |
| Earnings | JP¥48.54m |
Last Reported Earnings
Jan 31, 2025
Next Earnings Date
Jun 12, 2025
| Earnings per share (EPS) | 2.45 |
| Gross Margin | 52.61% |
| Net Profit Margin | 1.20% |
| Debt/Equity Ratio | 0% |
How did 4880 perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 19:31 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2025/01/31 |
| Annual Earnings | 2024/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CellSource Co., Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |
| Masatoshi Nagata | Ichiyoshi Research Institute Inc. |
| Kyoichiro Shigemura | Nomura Securities Co. Ltd. |